Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

XTX202

Fusion protein · Immune activation, directed at IL-2 receptor beta subunit (CD122) (IL2RB) and IL-2 receptor gamma subunit (CD132) (IL2RG) · developed by Xilio Development

Phase 1/2 Most advanced trial (none active)
XLO Developer
1 Registered trials

What is XTX202?

XTX202 is a protease-masked form of recombinant interleukin-2 that stays inactive until cleaved by proteases in the tumor microenvironment. Once released, IL-2 binds the CD122 and CD132 subunits on CD8+ T effector cells and natural killer cells, activating them against tumor cells. It is studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Fusion protein
Targets
IL-2 receptor beta subunit (CD122) (IL2RB), IL-2 receptor gamma subunit (CD132) (IL2RG)
Mechanism
Immune activation, directed at IL-2 receptor beta subunit (CD122) (IL2RB) and IL-2 receptor gamma subunit (CD132) (IL2RG)
Pathways
IL-2R-mediated signaling, T-cell and NK cell activation, cytolytic immune response
Therapy area
Oncology
Developer
Xilio Development, Inc. (XLO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05052268 Phase 1/2 Advanced Solid Tumor Completed XLO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on IL2RB / IL2RG

More from Xilio Development

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XLO page.

Follow XLO, the company behind XTX202

See XLO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XLO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.